Commercialization Plan. As soon as reasonably practicable, but no later than ​ after the first MAA for a Product is submitted in the Territory, Licensee shall prepare and present to the JSC for review and discussion a reasonably detailed plan for the commercialization of the Product in the Field in the Territory (the “Commercialization Plan”). Licensee shall update and amend the Commercialization Plan on an annual basis following the First Commercial Sale of the Product in the Field in the Territory and present such updates and any amendments to the JSC for review and discussion.

Commercialization Plan. Beginning ​ (​) calendar quarters prior to the anticipated First Commercial Sale of a Licensed Product in the Field in the Territory, Licensee shall provide a written plan to the Commercialization Committee for review and approval (the Commercialization Plan) setting forth in reasonable detail the planned Commercialization activities (or preparations for First Commercial Sale, as applicable) in relation to the Licensed Products planned for the four (4) calendar quarters following such quarter. Each Commercialization Plan shall include at least the information as set forth in [Schedule 6.3] to this Agreement. Such Commercialization Plan shall be updated, reviewed, and approved by the Commercialization Committee ​ at least on an annual basis.

Commercialization Plan. The Commercialization Plan shall contain in reasonable detail the significant Commercialization activities and the projected timelines for achieving such activities, including ​ in the Territories. Zai shall deliver an initial Commercialization Plan to the JSC for review and discussion no later than ​ of the first Regulatory Approval Application for a Product in the Territory. Thereafter, from time to time, but at least once every ​ months, Zai shall propose updates or amendments to the Commercialization Plan to reflect changes in such plans, including those in response to changes in the marketplace, relative success of the Products, and other relevant factors influencing such plan and activities, and submit such proposed updated or amended Commercialization Plan to the JSC. In preparing the initial Commercialization Plan and any updates or amendments thereto, Zai shall provide TPTX with an opportunity to comment and Zai shall consider any TPTX’s comments in good faith in finalizing the initial Commercialization Plan and any updates or amendments thereto.

Commercialization Plan. No later than ​ before the anticipated date of the submission of the first NDA for the Product in the Field in the Territory, Ji Xing shall submit to the JCC for review and discussion a written Commercialization plan that sets the timeline and details of all major Commercialization activities planned for the Product in the Territory (the “Commercialization Plan”). Thereafter, from time to time, but at least ​, Ji Xing shall prepare updates or amendments to the Commercialization Plan to reflect changes in such plans, including those in response to changes in the marketplace, relative success of the Product, and other relevant factors influencing such plan and activities, and submit such updated or amended plan to JCC for review and discussion before such updates and amendments become effective. Except as expressly agreed by [[Cytokinetics:Organization]] in writing or to the extent required by the applicable Regulatory Authority or to address specific operational requirements in the Territory, the Commercialization Plan shall be ​ for the Product, and the Commercialization of the Product in the Territory shall be conducted in accordance with the Commercialization Plan as amended from time to time.

Commercialization Plan. At least [​] days in advance of the anticipated [​] of a Licensed Product in [​] in the Territory, Bayer shall prepare and submit to Atara a written plan setting forth the activities to be undertaken with respect to the Commercialization of Licensed Products (the “Commercialization Plan”), which shall describe in reasonable detail Bayer’s Commercialization activities for the rest of the relevant [​]. Thereafter, Bayer shall prepare and submit to Atara for the rest of the term of the Agreement a Commercialization Plan on any new [​] no later than [​] days after [​].

Commercialization Plan. No later than ​ before the anticipated date of the submission of the first NDA for the Product in the Field in the Territory, Ji Xing shall submit to the JCC for review and discussion a written Commercialization plan that sets the timeline and details of all major Commercialization activities planned for the Product in the Territory (the “Commercialization Plan”). Thereafter, from time to time, but at least ​, Ji Xing shall prepare updates or amendments to the Commercialization Plan to reflect changes in such plans, including those in response to changes in the marketplace, relative success of the Product, and other relevant factors influencing such plan and activities, and submit such updated or amended plan to JCC for review and discussion before such updates and amendments become effective. Except as expressly agreed by [[Cytokinetics:Organization]] in writing or to the extent required by the applicable Regulatory Authority or to address specific operational requirements in the Territory, the Commercialization Plan shall be ​ for the Product, and the Commercialization of the Product in the Territory shall be conducted in accordance with the Commercialization Plan as amended from time to time.

Commercialization Plan. At least ​ months before the scheduled date of the first BLA submission for a Licensed Product in its Territory, Kyorin will prepare and deliver to the JSC for review, input and approval, a reasonable draft written plan that summarizes the Commercialization activities (including any pre-Regulatory Approval activities in preparation for commercial launch) to be undertaken with respect to such Licensed Product in the Kyorin Territory, where such plan will include marketing and promotional activities for such Licensed Product in the Kyorin Territory aligned with the commercial positioning and the key messages approved by the JSC and will not be prepared in a manner that would adversely affect the Commercialization of the Licensed Products by or on behalf of aTyr in the United States (as updated or amended, the “Commercialization Plan”). Updates and modifications of the Commercialization Plan for a Licensed Product may be proposed by Kyorin for approval by the JSC, from time to time and no less frequently than ​, based upon, among other things, Kyorin’s Commercialization activities with respect to such Licensed Product in the Kyorin Territory.

Commercialization Plan. As soon as reasonably practicable, but no later than ​, Licensee shall prepare and present to the CGB a reasonably detailed plan for the Commercialization of the Product in the Licensee Territory (the “Commercialization Plan”). The Commercialization Plan will include specific information on a country-by-country basis, as Certain identified information marked with ​ has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.

Commercialization Plan. As soon as practicable, but not later than ​ each Party will prepare and provide to the JSC a Commercialization Plan for which such Party will conduct Commercialization in the respective Territory for such Collaboration Product. If FATE has exercised the FATE CDCC Option, a Commercialization Plan for which the Parties will conduct Commercialization in the FATE CDCC Territory will be prepared pursuant to [Section 2.4.4(b)] (CDCC Option). The applicable Party(ies) will prepare and provide a budget with respect to the activities covered by such Commercialization Plan. The applicable Party(ies) shall continue to provide to the other Party, through the JSC, regular updates from time to time to its Commercialization Plan, as applicable. The applicable Party(ies) will consider in good faith the other Party's comments on such Commercialization Plan and any updates thereto.

Commercialization Plan. At least ​ before the anticipated First Commercial Sale of the Product in the Field in a country in the Territory, MTPC will provide a strategic commercialization plan for the Products in the Field in the Territory for review and approval by the JSC (any such approved plan, the “Commercialization Plan”). The Commercialization Plan will set forth, among other things, # ​ marketing strategy that includes plans for market research, health economics, pricing and reimbursement, medical affairs and value added initiatives; # ​ communications strategy that includes plans for public relations, conferences and exhibitions and other external meetings and communications, publications and symposia, and internet activities; # a high level operating plan for the implementation of such strategies on ​ basis, including, without limitation, information related to product positioning, core messages to be communicated, and pricing strategies; # revenue targets and unit forecasts, planned for Products in the Territory and the timelines for achieving such activities; and # all other activities to be conducted by MTPC in connection with the Commercialization of Products in the Territory. During the Term, MTPC will amend the Commercialization Plan on an ongoing basis as necessary, any amendments (other than amendments required to comply with Applicable Laws or written requirements imposed by Regulatory Authorities) being subject to review and approval by the JSC, and any amendments required to comply with Applicable Laws or written requirements imposed by Regulatory Authorities being subject to report to the JSC. The Commercialization Plan must at all times contain terms that reflect the use of Commercially Reasonable Efforts to Commercialize all Products that have Regulatory Approval in the Territory and, except as otherwise expressly allocated to Viela in this Agreement, including in [Section 4.6.3] (Commercialization Cooperation), may not include any activities to be conducted by Viela, without Viela’s prior consent, which shall not be unreasonably withheld.